| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | C3/C5 convertase; Complement factor B; PBF2; Properdin factor B;;Complement factor B |
| WB Predicted band size | Calculated MW: 86 kDa ; Observed MW: 100 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Complement factor B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Complement Factor B抗体的3篇参考文献示例，包含文献名称、作者及摘要概述：
---
1. **"A monoclonal antibody specific for human complement factor B"**
*Author: Smith J, et al.*
*摘要：* 本文报道了一种新型单克隆抗体的开发，该抗体特异性识别人补体因子B(CFB)。通过ELISA和Western blot验证了抗体的特异性，并在补体激活途径的功能研究中展示了其应用潜力。
2. **"Complement factor B antibody inhibits lupus nephritis in a murine model"**
*Author: Chen L, et al.*
*摘要：* 研究利用抗补体因子B抗体治疗小鼠狼疮性肾炎模型，发现其能有效抑制补体替代途径的过度激活，减少肾脏炎症和病理损伤，提示CFB抗体在自身免疫疾病中的治疗价值。
3. **"Role of complement factor B in age-related macular degeneration: Insights from antibody-based modulation"**
*Author: Johnson R, et al.*
*摘要：* 通过靶向CFB的抗体干预，研究揭示了补体替代途径在年龄相关性黄斑变性(AMD)发病中的作用，为抗CFB疗法在眼科疾病中的应用提供了实验依据。
---
注：以上为模拟参考文献，实际引用时建议通过PubMed或Google Scholar检索最新文献(关键词：Complement factor B antibody, CFB antibody)。如需具体文章，可提供更详细的研究方向进一步筛选。
Complement factor B (CFB) is a critical serine protease in the alternative pathway of the complement system, an essential component of innate immunity. It circulates as a proenzyme and binds to activated C3b, forming the C3 convertase (C3bB), which is stabilized by properdin. Upon cleavage by factor D, CFB generates the active fragments Ba and Bb, with Bb retaining enzymatic activity to drive downstream complement activation, including the formation of the membrane attack complex (MAC) and amplification of inflammatory responses.
Antibodies targeting CFB are vital tools for studying its role in complement-mediated diseases, such as age-related macular degeneration (AMD), autoimmune disorders, and inflammatory conditions. These antibodies enable detection of CFB in various biological samples (e.g., plasma, tissues) using techniques like ELISA, Western blotting, and immunohistochemistry. Researchers also utilize CFB antibodies to investigate its interaction with other complement components, assess its activation status, or evaluate therapeutic interventions targeting the alternative pathway.
Dysregulation of CFB is linked to pathological inflammation and tissue damage, making it a potential biomarker or therapeutic target. Inhibitors of CFB, including monoclonal antibodies, are under exploration for conditions like paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune kidney diseases. CFB-specific antibodies thus serve both diagnostic and research purposes, bridging mechanistic studies and clinical applications in complement-related disorders.
×
